Cellular therapies, including autologous stem cell transplant (ASCT), allogeneic
hematopoietic cell transplantation (alloHCT), and chimeric antigen receptor-(CAR-) T cell …

Multiple myeloma (MM) is a chronic hematologic malignancy that remains incurable,
because most patients eventually relapse or become refractory to current treatments. MM is …

Survival has improved in patients diagnosed with multiple myeloma (MM) over the last two
decades; however, there remains a paucity of data on the causes of death in MM patients …

Abstract Purpose of Review As the treatment landscape for multiple myeloma (MM)
continues to expand at a rapid pace, management of older adults and frail patients becomes …

Geriatric assessment management is a multidimensional tool used to evaluate prognosis for
clinical outcomes and targets for interventions in older adults with cancer receiving …

T-cell redirecting therapy (TCRT), specifically chimeric antigen receptor T-cell therapy (CAR
T-cells) and bispecific T-cell engagers (TCEs) represent a remarkable advance in the …

Background T-cell–redirecting therapies, such as bispecific antibodies and chimeric antigen
receptor T-cells, exploit the cytotoxic capabilities of the immune system to destroy cells …

There is limited knowledge regarding the prevalence of geriatric impairments and frailty
among patients with multiple myeloma (MM) in a real-world setting. This study evaluated the …

Minimal (or measurable) residual disease (MRD) negativity has emerged as one of the most
important prognostic tools in multiple myeloma (MM) and is associated with significant …

Multiple myeloma (MM) is a highly heterogeneous hematological malignancy originating
from B lymphocytes, with a high recurrence rate primarily due to drug resistance. 2-((1H …